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Abstract
LCAT (lecithin:cholesterol acyltransferase) catalyzes the transacylation of a fatty acid of lecithin to cholesterol, generating a
cholesteryl ester and lysolecithin. The knowledge of LCAT atomic structure and the identification of the amino acids relevant
in controlling its structure and function are expected to be very helpful to understand the enzyme catalytic mechanism, as
involved in HDL cholesterol metabolism. However - after an early report in the late ‘90 s - no recent advance has been made
about LCAT three-dimensional structure. In this paper, we propose an LCAT atomistic model, built following the most up-to-
date molecular modeling approaches, and exploiting newly solved crystallographic structures. LCAT shows the typical
folding of the a/b hydrolase superfamily, and its topology is characterized by a combination of a-helices covering a central
7-strand b-sheet. LCAT presents a Ser/Asp/His catalytic triad with a peculiar geometry, which is shared with such other
enzyme classes as lipases, proteases and esterases. Our proposed model was validated through different approaches. We
evaluated the impact on LCAT structure of some point mutations close to the enzyme active site (Lys218Asn, Thr274Ala,
Thr274Ile) and explained, at a molecular level, their phenotypic effects. Furthermore, we devised some LCAT modulators
either designed through a de novo strategy or identified through a virtual high-throughput screening pipeline. The tested
compounds were proven to be potent inhibitors of the enzyme activity.
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Introduction
Protein members of the a/b hydrolase superfamily, present in
all living organisms, share the same structural architecture but do
not have common functions. This implies that the same fold has
been used through evolution for a number of different functions
including the catalytic activity as, for instance, hydrolase and
esterase [1]. The canonical fold of this superfamily consists of an 8-
stranded, mainly parallel, b-sheet surrounded by a-helices, in
which the second strand is oriented in the antiparallel direction.
No sequence similarity can be detected among the members of this
superfamily [2]. LCAT (phosphatidylcholine-sterol acyltransfer-
ase, EC 2.3.1.43) belongs to the a/b hydrolase folding superfamily
and shares the Ser/Asp-Glu/His triad with lipases, esterases and
proteases, as already thoroughly discussed by Peelman et al. in
1998 [3].
The LCAT reaction consists in a trans-esterification, in which a
fatty acid at the sn-2 position of phosphatidylcholine, or lecithin, is
transferred to the free hydroxyl group of cholesterol, and in the
meantime phosphatidylcholine is converted into lysophosphatidyl-
choline. However, at an atomic level, the mechanism is not yet
accurately described [3].
LCAT catalyses the synthesis of most plasma cholesteryl esters
(CE) [4,5]. The preferred lipoprotein substrate for LCAT is a
newly assembled small discoidal HDL and LCAT activity
modulates its assembly [6].
Mutations in the LCAT gene cause two rare disorders, namely
familial LCAT deficiency [7], FLD (MIM n. 245900) and fish-eye
disease [8], FED (MIM n. 136120). In FLD, plasma LCAT is
either absent or completely lacks catalytic activity; in FED, the
mutant LCAT lacks activity on HDL lipids but esterifies
cholesterol bound to apolipoprotein (apo)B-containing lipopro-
teins. In order to discriminate between FLD and FED in carriers
of two mutant LCAT alleles, it is mandatory to measure the ability
of plasma to esterify cholesterol; a differential diagnosis cannot be
defined only from the molecular characteristics of the carriers.
Knowledge of LCAT atomic structure and identification of the
amino acids relevant in controlling LCAT structure and function
is expected to be very helpful in understanding its catalytic
mechanism and its role in cholesterol metabolism. To date, the
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structure of LCAT has not been experimentally solved [9,10]. The
limiting step is represented by the enzyme purification from
human plasma: LCAT is not present at a high concentration, and
is strongly associated to lipoproteins. An alternative approach to
obtain the LCAT atomic structure may be based on molecular
modeling through up-to-date in silico procedures.
Modeling LCAT structure, however, faces a number of
problems. LCAT lacks an appropriate template for a straightfor-
ward homology modeling: the protein has a very low sequence
identity with all available templates, even if the secondary
structure motives of a/b hydrolases are easy to recognize. In the
past, Peelman et al. [3] tried to model the protein structure
following a smart strategy: LCAT N2terminus (residues 732210)
was modeled on human pancreatic lipase and the active site (aa
3332399) was completed based on C. antarctica lipase structure; the
remaining part of LCAT was not modeled.
In this paper, we can go further and propose a new LCAT
atomistic model. It was built combining the most up-to-date in
silico approaches and exploiting some crystallographic structures
solved in recent years. Among the latter, we selected two protein
structures useful to build the 3D LCAT model: PhaZ7depolymer-
ase from Paucimonas lemoignei [11], and Lipase A from Candida
antarctica [12]. The model was successfully validated in two ways.
Some natural mutations were selected and structural details of the
active site, of the catalytic triad and the oxyanion hole were used
for a molecular explanation of their phenotypic effects. Then, we
identified molecules able to inhibit LCAT enzymatic activity.
These were either designed by a de novo strategy or identified
through a virtual high-throughput screening pipeline; we could
confirm their binding to the LCAT pocket by in vitro and in vivo
activity assays.
Materials and Methods
Comparative Modelling
The human LCAT primary structure was downloaded from the
UniProt-Protein Knowledgebase database (entry UniProt ID:
P04180), and the signal peptide primary structure was removed.
Starting from its sequence, a three-dimensional model was built
based on multiple templates and ab initio modeling. Since a
homologous template search on the full LCAT sequence did not
provide any suitable solution, the LCAT primary structure was
split in two parts, an N-terminal and a C-terminal ‘domain’. These
domains do not correspond to true structural domains, but they
were useful to find suitable templates for successful distant
homology modeling procedures. We split the sequence in two
portions of similar size, with a small overlapping region, suitable to
drive domain merging. We also separated the catalytic triad,
taking Ser181 in the N-terminal and Asp345 and His377 in the C-
terminal parts: the triad interaction network would then assess the
reliability of the model assembly procedure.
We separately submitted both LCAT parts to the Fold
Recognition PSIPRED default procedure. We found 2VTV
(PhaZ7depolymerase from Paucimonas lemoignei, UniProt ID:
Q939Q9; identity: 19.5%) as a suitable template for LCAT N-
terminus, and 2VEO (Lipase A from Candida antarctica, UniProt
ID: D4PHA8; identity: 14.5%) as a template for LCAT C-
terminus. All the modeling procedures were carried out with
modules of the suite Molecular Operating Environment 2008.10
(MOE).
The alignment of the sequences of target and template proteins
was produced with the Align program of MOE using default
parameters, and it was manually adjusted making reference to the
BLASTP output. This alignment was set as reference for all the
homology modeling procedures.
Comparative model building was carried out with the MOE
Homology Model program. 2VTV was set as template for LCAT
residues 44–210 and 2VEO for residues 200–416. Ten indepen-
dent models were built, refined and scored with GBIV scoring
function, and then the highest-scoring intermediate model was
submitted to a further round of energy minimization (EM). Both
for the intermediate and the final structures the refinement
procedures consisted in EM runs based on the AMBER99
forcefield, with the reaction field model, down to a gradient of
1025 kcal/mol/A˚2.
The two disulfide bonds of the protein, between Cys 50 and Cys
74, and between Cys 313 and Cys 356, were built through the
MOE Builder module. Only nine structures had the cysteines of
each pair sufficiently close to build of a disulfide bond; the best
model had a distance of 5.5 A˚ for the pair Cys50–Cys74 and a
distance of 5.18 A˚ for the pair Cys313–Cys356.
The quality of the final model was carefully checked with the
MOE Protein Geometry module to make sure that the stereo-
chemical quality of the proposed structure was acceptable. No
further model quality estimations were run, because it is well-know
that membrane or lipid-associated proteins, such as LCAT, obtain
low scores, since their physico-chemical properties differ consid-
erably from those of soluble proteins [13].
At the same time, we submitted the primary structure of LCAT
to David Baker group’s Robetta Web Server, which uses the
Rosetta software package, setting default parameters [14]. From
the output, we selected the model with the correct general
topology [3], the correct geometry of the catalytic triad [3,15], and
the most favourable rotamer conformations of side chains in order
to form cysteine disulfide bridges.
From the above, once we obtained the two structures, that by
comparative modeling and that by ab initio modeling, we built a
‘structural chimera’, setting the previous distant homology model
as the template for the whole protein and the Robetta de novo
model as template for residues 1–43; the option ‘Use Selected
Residues to Override Template(s)’ was checked in order to
override the primary template with the more appropriate ones
Table 1. Stability score of WT and T274 mutant LCAT.
Mutation Stability* [kcal/mol] dStability** [kcal/mol]
T274 (WT) 27.37 0.00
T274A 26.12 0.27
T274I 29.25 22.87
*Stability is the absolute thermostability of the mutation and, for the generated ensemble, it is equal to the Boltzmann average of the stabilities of the ensemble.
**dStability is the relative thermostability of the mutation in comparison with the wild-type protein, and it is equal to the Boltzmann average of the relative stabilities of
the ensemble.
doi:10.1371/journal.pone.0095044.t001
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only for the selected residues. Summing up, the residues from 1 to
43 were modeled ab initio by Robetta Server, the residues from 44
to 210 were modeled on 2VTV, and the residues from 211 to 416
were modeled on 2VEO. The modeling of residues from 1 to 91
has a low accuracy due to the combination of ab initio modeling
and a low quality of the local alignment. All models were
minimized and geometrically and energetically evaluated as
already described above. Both disulfide bonds were set as
described above. The LCAT binding site was identified through
the MOE Site Finder module.
Mutation Analysis
For all the selected residues, we performed the mutations
through the MOE Mutate program in MOE Edit module, and we
evaluated the best energetic orientation of side chains through the
MOE Rotamer Explorer program in MOE Protein module.
For the Thr274 [Ala/Ile] mutations, we assessed the influence
on protein unfolding free energy by using Protein Design module,
a tool of MOE 2012.10 (Molecular Operating Environment,
MOE). We refined the Thr274Ala and Thr274Ile mutations using
the Protonate 3D MOE tool into the Protein Design applications,
with default parameters and based on Amber12EHT forcefield
with distance dependent dielectric form to model the solvent
effects on electrostatics. Then we computed the DDGs according
to the following stability scoring function functional form:
DDGs~a DEvdwz0:5 DEcoulzDEsolð Þ½ 
zbDESSzcDSASCzDG
WT?Mut
uf
ð1Þ
where DEvdw is the AMBER van der Waals interaction energy,
DEcoul is the AMBER Coulomb interaction energy, DEsol is the
change in solvation energy calculated using GBVI, and ESS is the
change in energy due to the presence of a disulfide bond. The last
term, c?DSAsc is a residue-dependent change in surface area
(associated to entropy). We also generated an ensemble of protein
conformations for both the Thr274 mutants using MOE Low-
Mode MD with default parameters, and based on Amber12EHT
forcefield, with distance dependent dielectric form to efficiently
search for the conformational space of the wild type and of the
mutant protein forms.
In detail, for the generated ensemble, we evaluated Stability, the
absolute thermostability of the mutation, which is equal to the
Boltzmann average of the stabilities of the ensemble, and
dStability, the relative thermostability of the mutation with respect
to the wild-type protein, computed as Boltzmann average of the
relative stabilities of the ensemble [16,17]. A DDGs negative value
points to a mutation able to stabilize the protein; on the contrary a
Figure 1. Superposition of the top 10 conformations obtained by LowMode MD for wild-type LCAT and T274[A/I] mutants. Protein
backbone is rendered in ribbons, whereas Phe103, Ser181 and Thr274[Ala/Ile] side chains are rendered as sticks. Color code: wild-type LCAT=orange,
T274A=blue, T274I = green.
doi:10.1371/journal.pone.0095044.g001
Table 2. Physico-chemical parameters for the two top-scoring ligands.
Ligand MM/GBIVdocking score [kcal/mol] Affinity (pKi)
Compound #1 27.36 5.84
Compound #2 27.29 5.39
doi:10.1371/journal.pone.0095044.t002
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positive DDGs suggests a mutation, which reduces the global
protein stability.
Molecular Docking
The Asinex Platinum Collection (http://www.asinex.com) is a
lead-like structural library containing approx. 130,000 in-house
synthesized compounds. The SD file containing all the structures
was downloaded and the MOE Conformation Import module was
run on this file to produce a single, low-energy conformation for
each putative ligand contained in the Asinex SD file. All the
docking procedures were carried out with the suitable MOE
programs.
The in silico screening was carried out with the Dock program
contained in the MOE Simulation module. The full LCAT
structure was set as Receptor. The binding site was defined with
dummy atoms positioned through the MOE Site Finder module.
Before starting with the placement procedure, 1000 conformations
were generated for each ligand by sampling their rotatable bonds.
The selected placement methodology was Triangle Matcher, in
which the pre-refined poses are generated by superposing triplets
of ligand atoms and triplets of receptor site points. The protein site
points are alpha spheres centres that represent locations of tight
packing. Before scoring all the generated poses, duplicate
complexes were removed. Poses are considered as duplicates if
the same set of substrate-enzyme atom pairs are involved in
hydrogen-bond interactions and the same set of ligand atom-
protein residue pairs are involved in hydrophobic interactions.
The accepted poses were scored according to the London dG
scoring, which estimates the free energy of binding of the ligand
from a given pose:
DG~czEflexz
X
h{bonds
cHBfHBz
X
m{lig
cMfMz
X
atoms i
DDi ð2Þ
where c represents the average gain/loss of rotational and
translational entropy; Eflex is the energy due to the loss of flexibility
Figure 2. Molecular docking results: a) lowest energy pose in LCAT binding site for heptadecylcholesteryl R phosphonyl chloridate
b) compound #1 and c) compound #2 and its chemical structures. The surface of the protein binding site is colored according to
lipophilicity (hydrophilic area in blue in grey, lipophilic in gold and neutral in white).
doi:10.1371/journal.pone.0095044.g002
Table 3. In vitro inhibitory assays on LCAT of the heptadecylcholesteryl (R, S) phosphonyl chloridate and the two top-scoring
compounds.
Inhibitor concentration
[mM]
heptadecylcholesteryl (R, S) phosphonyl chloridate %
inhibition
Compound #1 %
inhibition
Compound #2 %
inhibition
0.046 0.00 25.364.1 30.260.0
0.091 0.00 69.365.1 36.164.2
0.182 0.00 41.662.3 45.368.0
0.364 0.00 88.866.8 51.662.7
0.730 16.668.8 10060.0 10060.0
1.420 33.864.6
2.680 54.665.2
6.620 10060.0
Approx. IC50 2.1 0.1 0.3
doi:10.1371/journal.pone.0095044.t003
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of the ligand (calculated from ligand topology only); fHB measures
geometric imperfections of hydrogen-bonds and takes a value in
[0,1]; cHB is the energy of an ideal hydrogen-bond; fM measures
geometric imperfections of metal ligations and takes a value in
[0,1]; cM is the energy of an ideal metal ligation; and Di is the
desolvation energy of atom i. The difference in desolvation
energies is calculated according to:
DDi~ciR
3
i
ððð
u=[A|B
DuD{6du{
ððð
u=[B
DuD{6du
8><
>:
9>=
>; ð3Þ
where A and B are the protein and/or ligand volumes with atom i
belonging to volume B; Ri is the solvation radius of atom i (taken as
the OPLS-AA van der Waals sigma parameter plus 0.5 A˚ ); and
ci is the desolvation coefficient of atom i. The coefficients (c, cHM,
cM, ci) have been fitted from approx. 400 X-ray crystal structures of
protein-ligand complexes with available experimental pKi data.
Atoms are categorized into about a dozen atom types for the
assignment of the ci coefficients. The triple integrals are
approximated using Generalized Born integral formulas. Only
the top scoring solution was kept and submitted to a further
refinement step, via molecular mechanics (MM) based on
MMFF94x. In order to speed up the calculation, residues over a
6 A˚ cut-off distance away from the pre-refined pose were ignored,
both during the refinement and in the final energy evaluation. All
receptor atoms were held fixed during the refinement. During the
course of the refinement, solvation effects were calculated using
the reaction field functional form for the electrostatic energy term.
The final energy was evaluated using the MMFF94x forcefield
with the Generalized Born solvation model (GBIV) [18]. All the
ligands contained in the Platinum library were screened according
to the above procedure. Once sorted by their docking score, we
selected the best docking poses and only the two top scoring
compounds were resubmitted to the same docking procedure,
keeping for each of them 300 poses. Both were eventually bought
from Asinex and tested in in vitro assays.
We designed an irreversible inhibitor, connecting a molecule of
cholesterol through a phosphonyl chloride group to a 17-carbon
atom chain. We evaluated in silico both its enantiomers, R and S,
for interaction with LCAT by performing a molecular docking,
using the Dock program in the MOE Simulation module. After
generating 1000 conformations, we produced 100 poses for both
molecules using the AlphaPMI placement methodology, useful for
docking to a tight pocket. The accepted poses were assessed
according to the London dG score and refined through a MM step
based on MMFF94x with the GBIV solvation model. We selected
the best poses for R and S enantiomers and, using the Binding tool
in MOE suite, we covalently bound in silico both molecules to the
catalytic serine of LCAT. We then performed an EM step, based
on MMFF94x with the GBIV solvation model, down to a gradient
of 1025 kcal/mol/A˚2. The accurate docking procedure described
above for the chemical library items was applied to the de novo
designed compound.
The estimated binding affinities were calculated through the
MOE LigX module. The prediction of pKi values (-Log of the
dissociation constant) was computed through the London dG
scoring function and the Lig X MOE module, after a further local
refinement of the docked complexes into the LCAT active site.
This and other empirical scoring functions are useful to rank the
complexes according to their dissociation constant, as already
discussed by Eberini et al. [19].
In vitro Assays
Plasma obtained from a control subject was added with
increasing concentrations (0.046–6.620 mM) of LCAT modulators
or saline and cholesterol esterification rate (CER) was assessed by
measuring changes in plasma unesterified cholesterol concentra-
tions [20].
The ability of the LCAT irreversible modulator to bind
recombinant human LCAT [21] was tested by mass spectrometry.
Molecular weight was determined by a Bruker Daltonics Reflex IV
instrument (Bruker Daltonics, Bremen, Germany) equipped with a
nitrogen laser (337 nm) and operated in positive mode using
sinapinic acid in 01% TFA: CH3CN = 2:1 as matrix. External
standards were used for calibration (Bruker protein calibration
standard).
In vivo Assays
Animal care and experimental procedure were performed with
the approval of the local ‘‘Comitato Etico per la Sperimentazione
Animale’’, overseeing animal experiments at University of Parma.
No special permission for use of animals (mice) in such
pharmacological studies is required in Italy, as defined by the
legislative decree 116/92.
Twelve week old male C57BL/6J mice were housed in a
controlled environment at 2562uC with alternating 12 h light and
dark cycles and received standard diet and water ad libitum. Mice
(n = 5) were treated intraperitoneally with the covalent inhibitor at
a dose of 150 mg/kg. Blood samples were collected at different
times after treatmentand recovered in plastic tubes containing
sodium citrate 3.8%. Plasma was isolated by low speed centrifu-
gation and stored at 280uC until use. Plasma total and
unesterified cholesterol were measured by enzymatic techniques,
and LCAT activity was measured on plasma samples using
reconstituted HDL as substrate [22].
Results and Discussion
Comparative Modelling
The PDB Search module of the MOE Suite was unable to
identify any suitable template(s) for full LCAT modeling. Also
Table 4. Mass spectrometry data of human recombinant LCAT and of the covalent adduct between LCAT and its irreversible
inhibitor.
MW (calculated)* (Da) MW (experimental) (Da)
LCAT 47083.9 57800.9
LCAT+inhibitor 47726.9 (+643) 58445.6 (+644.7)
*Molecular weight calculated from the aminoacid sequence. An increase of 643 Da is expected in the presence of one molecule of inhibitor bound to the protein. The
higher MW experimentally observed for LCAT in comparison with the value calculated from the sequence can be ascribed to the glycosylation of the protein.
doi:10.1371/journal.pone.0095044.t004
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submitting the entire LCAT sequence to the Fold Recognition of
PSIPRED server [23] did not identify any useful entry, and the
best matching protein with a solved structure was a hydrolase from
Lactobacillus plantarum (PDB ID 3LP5, UniProt ID: F9UMW5).
However, the latter shares with LCAT only 16% identity - a level
of similarity insufficient to produce any acceptably accurate model.
All the identified templates belong to the fold superfamily of a/b-
hydrolases, confirming previous hypotheses that LCAT belongs to
it. Scanty results were likewise obtained by using the template
identification tool of the Swiss-Model web site (http://swissmodel.
expasy.org), which carries out a multi-level search based also on
Hidden Markov Models (HMM). This tool is not based only on
the search for identity, but is sensitive enough to detect distant
relationships among protein families [24]. The application of
homology modeling procedures can produce very reliable and
useful results also when the identity between target and template
sequences is very low (approx. 20%). If the general topology and
the secondary structure of the target protein is known, the
alignment procedure can be carried out more confidently through
the use of these supplementary data. Typical example is the
modeling of class-A GPCR [25], receptors with a peculiar
topology, that can be easily managed through classical compar-
ative methods, despite their low sequence identity with the
available templates. Recently, we focused our attention on
modeling of GPR17, a class-A GPCR, and successfully identified
very potent orthosteric agonists of this receptor [19]. LCAT
topology and local secondary structure have been thoroughly
discussed and are well-defined [3]. These data are very useful for
guiding a better alignment between target and template sequences,
and for obtaining a more reliable three-dimensional model.
An effective strategy to try overcoming the lack of a single whole
suitable template is building homology models of distinct parts of a
protein, and then merging them in a single model that can be
defined as a ‘structural chimera’ [19]. Indeed, we had better
success after splitting the LCAT primary structure approx. in two
halves, which allowed the identification of two templates useful to
carry out LCAT distant homology modeling, as already suggest by
Peelman et al. [3]. As reported in the ‘Materials and Methods’
section, to guide merging we identified a partially overlapping
portion (residues 200–210), thus splitting the catalytic triad
between the two ‘domains’ (Ser181 in the N-terminal, and
Asp345 and His377 in the C-terminal domain). Submitting the
N-terminal (residues 1–210) and C-terminal (residues 200–416)
LCAT sequences, we obtained two series of putative templates,
with higher identity to the targets than Lactobacillus plantarum
hydrolase, but still under 30%.
In detail, as template for LCAT N-terminus, we found 2VTV
(PhaZ7 depolymerase from Paucimonas lemoignei, UniProt ID:
Q939Q9. Identity: 19.5%) and, for LCAT C-terminus, 2VEO
(lipase A from Candida antarctica, UniProt ID: D4PHA8. Identity:
14.5%) (see Figure S1 in File S1).
The final comparative model matched the already reported
topology [2,3], in which we can identify the combination of a-
helices connected by variable loops and covering a central b-sheet.
In detail, the model presents the correct arrangement for the seven
strands in the central b-sheet (b2-b4-b3-b5-b6-b7-b8), and their
correct relative orientation, since b2 has antiparallel orientation
with respect to the other strands. The localization of the catalytic
residue Ser181 at the end of the b-strand 5, close to a-helices 5
and 6, is in line with previously published data.
In order to collect more knowledge about LCAT structure and
to manage these structural issues, we thus produced, in addition, a
de novo model of LCAT, by submitting to this purpose the primary
structure of LCAT, without its signal peptide, to the Robetta Web
Server. The de novo approaches to protein modeling have been
extensively analysed and evaluated in the most recent CASP
competitions [26], demonstrating that there are several cases in
which Rosetta has been able to predict structures with atomic level
accuracy better than 2.5 A˚ [27].
Only five of all de novo generated models had the correct general
topology; two of these lacked the correct geometry of the catalytic
triad, and were discarded without further investigations. In the
three remaining models, the possibility to form cysteine disulfide
bridges was evaluated: the C-terminal cystine was correctly
predicted in all of them, whereas no acceptable predictions were
obtained for the N-terminal cystine. Looking into the catalytic
triad, one of the three models presented a very favourable
interaction network and relative distances among the three
residues. Furthermore, also the localization of the oxyanion hole
was correctly predicted: this residue contributes to the stabilization
of the reaction intermediate [28] and is spatially close to the
catalytic triad residues. We selected this one as the best model
obtained from the de novo Robetta strategy.
In order to keep into account all structural information about
LCAT, we merged the homology and the de novo models in a new
final LCAT model, by adding to the homology model (residues
44–416) the residues 1–43 obtained from the ab initio modeling
procedure. The final model of LCAT is reported in Figure S2 in
File S1.
The catalytic triad of our proposed model appears correctly
predicted, when compared with the model proposed by Peelman
et al. [3], and with the model catalytic triad of a serine protease
from Bacillus lentus [15]. We also found general agreement of the
distances between the catalytic residues in our model with those
reported by Peelman et al. [3]: the distance between Oc in Ser181
and N2 in His377 was 5.41 A˚ versus an expected distance of 2.5 A˚,
the distance between Od in Asp345 and N1 in His377 was 4.63 A˚
versus an expected distance of 2.9 A˚, the distance between the
oxyanion hole (Phe103) and the catalytic triad was 6.75 A˚ versus an
expected distance of 5 A˚.
LCAT, which has both phospholipasic and acyltransferasic
activities, requires the possibility for both a lecithin and a
cholesterol molecule to enter the catalytic site. For this reason,
we expected to find in the LCAT structure a hydrophobic pocket
large enough to accommodate a CE, with an accessible catalytic
triad placed at its basis (active site), and not completely solvent-
exposed.
We used the MOE Site Finder tool to identify the binding site
for LCAT natural ligands. The analysis of LCAT through the
MOE Site Finder module revealed 27 putative binding sites; the
top-scoring contained 346 contact atoms, among which 73 were
hydrophobic and 256 corresponded to side-chain atoms. Since this
pocket, shown in Figure S2 in File S1, is located near the catalytic
triad, we accept this one as the putative LCAT binding site.
The scientific literature reports that mutation of Glu149
changes the fatty acid specificity and probably facilitates the
spatial accommodation of a bulkier arachidonic acid molecule in
the binding site [3,29]. As mapped on our model, Glu149 is
localized, as expected, in the loop between helices 4 and 5. It does
not directly faces the active site, but has a pivot role in a network of
hydrogen bonds with amino acids relevant for the binding site
structure. The loss of Glu149 side chain breaks this structural
network and makes the active site looser, as reported in Figure S3
in File S1.
In most lipases, it has been reported that a mobile lid covers the
substrate binding site, and enzyme activation occurs upon binding
to a hydrophobic substrate. In detail, in water, a lid closes the
entering channel for the active site, which opens only upon
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binding to a hydrophobic interface. Usually, the lid consists of a
single short helix, and it is closed onto the active site. In contrast to
the core of lipases, whose architecture is highly conserved, lids are
less conserved elements, with significant variations in their length
and different relative positions in the various lipases. In LCAT,
several experiments have pointed out an amphipathic region: an
a-helix in the N-terminus, closed, as in other lipases, by a
disulphide bridge (Cys50–Cys74) [10]. This region is identified as
an interfacial recognition domain for (apo)lipoproteins, and it
could not only serve as a binding site for the hydrophobic
substrates, but further include a ‘tilted’ peptide, which is thought
to destabilize the lipid substrate and facilitate the diffusion of a
monomeric phospholipid or triglyceride into the cavity of the
enzyme active site [30]. This region is distant from the enzyme
active site, which is located in the central core of the protein.
Contrary to the latter, which is more conserved and easier to
model, in our LCAT structure we then cannot properly define the
N-terminal lid region, because it is not sufficiently conserved.
Furthermore, the lid region requires a hydrophobic environment
for a complete and correct folding, and MM computations
accounting for a high and continuous dielectric effect are
inadequate to correctly model this part of the protein [29,30].
As already discussed, the LCAT N-terminus is associated with very
low accuracy, connected to the lack of homologous templates for
the residues from 1 to 43 and to a low quality of the local
alignment with the selected template for the region from 44 to 91.
Mutation Analysis
A validation of the structure suitability comes from the mapping
of known mutations, which cause familial LCAT deficiency [7],
FLD (MIM n. 245900), and fish-eye disease [8], FED (MIM
n. 136120), both characterized by very low levels of HDL [31].
We selected three mutations described in Italian carriers of LCAT
deficiency [31], Lys218Asn, Thr274Ala and Thr274Ile, and
evaluated their impact on the atomic structure [32,33].
When analysing the LCAT primary structure the impact of the
listed mutations is not obvious, because these amino acids are not
located in the immediate neighbourhood of the catalytic residues
nor directly affect them.
Mutation of Lys218 in Asn results in FLD in homozygous
carriers [31]. Modeling the entire enzyme and locating this
mutation on the LCAT three-dimensional structure, we find out
that the residue faces the active site, in the region that we assume
to behave as fatty acid cleft. This mutation modifies the
environment, since the residue changes from a charged (basic) to
a non-charged amino acid. In addition, we observe that this
mutation produces the disruption of the local hydrogen-bond
network. These changes strongly affect the fatty acid binding site
and may explain why the carriers of this mutation do not have a
functional enzyme and cannot produce cholesterol esters (see
Figure S4 in File S1).
Two different mutations for Thr274 have been reported [31];
Thr274Ala results in FED and Thr274Ile in FLD. Also in this
case, the atomic structure of LCAT helps us to explain the
different impact of the two mutations and to assess the quality of
the model.
As reported in Table 1, the three structures, wild-type and
mutated, have different stability scores. The Ala mutation results
in a negligible decrease in stability (dStability = 0.2696 kcal/mol),
whereas the Ile mutation considerably increases global protein
stability (dStability =22.8646 kcal/mol).
Thr274 is close to Phe103, which contributes to the definition of
the oxyanion hole (2.5 A˚), and its mutation into Ala increases the
environment hydrophobicity. We can assume that the local
conformational rearrangement due to the mutation results in a
change in the Phe103 side chain orientation, causing a difficulty in
enzyme-substrate binding and the occurrence of the FED
phenotype. The Ile residue is associated with a bigger steric bulk
than Ala, and this can cause a wider local rearrangement, moving
the Phe103 side chain almost completely into the binding pocket,
thus blocking LCAT enzymatic activity.
To validate these hypotheses, we performed a conformational
search on the wild-type and on the mutated structures; using the
LowMode MD method, we produced 25 different poses for each
structure and we analysed the 10 more energetically favourable
conformations. As reported in Figure 1, the T274A mutation (in
blue) causes a minimal change in Phe103 orientation versus the
wild-type molecule. Conversely, the T274I mutation (in green)
produces a more considerable rearrangement, and 4 structures out
of the 10 analysed present the Phe103 side chain in a position very
close to the catalytic serine, and a strong decrease of the binding
area. Indeed, no room remains for the stabilization of the
tetrahedral intermediate typical of a trans-esterification reaction,
and carriers of this mutation present FLD phenotype.
Molecular Docking
Searching for molecules targeting the LCAT binding site in a
large chemical library, we carried out the docking procedure in
two steps: i) quick docking and ii) accurate docking. To evaluate
the docking results in the final step of both procedures, we run
molecular mechanics refinement, and computed the final energy
score through an empirical scoring function based on the
MMFF94x forcefield with the generalized Born implicit solvation
model (MM/GBIV).
All ligands in the tested Asinex database were submitted to a
virtual HTS (high-throughput screening) procedure and were
evaluated using the quick docking procedure, refining and keeping
only the best solution for each ligand. The ligands corresponding
to the two best poses were submitted to the accurate docking
procedure, generating 300 solutions (poses) for each ligand. The
best solution for the ligands shows binding scores between 27.356
and 27.289 kcal/mol, as reported in Table 2.
The chemical structures of the two top-scoring compounds are
reported in Figure 2, panel b and c. They belong to different
chemical classes, suggesting that the in silico screening allowed us to
identify putative lead compounds with different features. The in
silico simulation provides evidence that both molecules completely
block the access to the LCAT active site, as shown in Figure 2,
panel b and c.
The docking score of the poses according to MM/GBIV and
the pKi values (-Log(Ki)), dissociation constant) computed with the
London dG scoring function after MOE LigX refinement show a
similar trend, suggesting that both these methods, based on
different scoring approaches, can be used to evaluate docking
results and to compute approximate binding free energies for the
system under investigation (see Table 2).
With the structural model of LCAT as reference, we were able
to design in addition a compound capable of acting as irreversible
inhibitor of the enzyme. Such a molecule may be potentially useful
as a tool in pharmacological research.
To design an inhibitor with a highly selective profile, we set to
mimic the II intermediate of the reaction catalysed by the enzyme
- a compound in which a cholesterol and a fatty acid molecule are
bound together. Indeed, the I reaction intermediate could be
common to other enzymes that share the same catalytic triad, and
this would certainly result in a loss of selectivity [34].
For this reason, we designed a compound joining a molecule of
cholesterol bearing a phosphonyl chloride group to a 17-carbon
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atom chain, an optimal length for the functionality of LCAT [35].
This resulted in the synthesis of a heptadecylcholesteryl-(R, S)-
phosphonyl chloridate, a compound that is able to fully occupy the
active site of LCAT, as shown by our simulation, see Figure 2,
panel a [36]. Since this molecule has a chiral centre (the
phosphorus atom), both enantiomers were tested in silico. After
docking both the R and S compounds, and after covalently linking
Ser181Oc to the phosphorus atom in the top-scoring complexes of
the two lists, we submitted them to a further energy minimization
step. The R-enantiomer complex turned out to have a more
favourable potential energy (22489.68 kcal/mol), whereas the S-
enantiomer has a potential energy of 22130.58 kcal/mol.
Furthermore, observing the binding site, only the R-enantiomer
seems to be properly placed and oriented for interaction with the
oxyanion hole, close to the Phe103 residue. A similar enantiomeric
preference had already been described for some lipases that share
the same catalytic triad as LCAT [37].
Even though the computational data suggest that the R-
enantiomer is stereochemically and energetically favoured (please,
see before), we used the readily available racemic mixture for the
in vitro tests of LCAT enzymatic activity. In order to compare the
complementarity of the irreversible inhibitor versus the reversible
ones with respect to LCAT, the non-covalent interaction energies
(disregarding the covalent bond) were computed in silico by using
the reported molecular docking protocol; the binding score had a
value of 28.49 kcal/mol.
The ability to affect the cholesterol esterification process of the
identified LCAT inhibitors (both the HTS molecules and the
covalent inhibitor) was assessed in vitro by the measurement of
CER in control human plasma in the absence and presence of
increasing amounts of the modulators. Each series of tests was
repeated three times; the results are reported in Table 3. All the
molecules are able to inhibit the enzyme in a dose-dependent
manner, although at different concentrations. The most efficacious
compound among the selected molecules completely inhibits
LCAT at a concentration between 0.364 to 0.730 mM, while the
heptadecylcholesteryl-(R, S)-phosphonyl chloridate does it at
6.620 mM. Data have been plotted in Figure S5 in File S1.
The only compound designed to irreversibly inhibit LCAT is
heptadecylcholesteryl (R, S) phosphonyl chloridate, because it has
acylating activity. In order to demonstrate that this compound is
able to acylate the catalytic Ser residue, we have carried out
MALDI-TOF analysis of the recombinant human LCAT [21]
before and after incubation with heptadecylcholesteryl (R, S)
phosphonyl chloridate. Through this approach, we demonstrated
the formation of a covalent bond between LCAT and the
inhibitor. Peaks at 57800.9 m/z and at 58445.6 m/z were
detected before and after LCAT incubation: the first one
corresponds to the free glycosylated enzyme, the latter to LCAT
bound to the inhibitor (Table 4).
When the heptadecylcholesteryl-(R, S)-phosphonyl chloridate
was injected intraperitoneally in mice, it inhibited LCAT activity
in plasma by 36% after 30 hours and by 100% 45 hours after
injection (LCAT activity at baseline: 3.6 nmol CE/ml/h 62.8),
and free/total cholesterol ratio increased from 0.3560.02 to
0.4160.06 and 0.3960.06 at 30 h and 45 h, respectively.
Conclusions
Our de novo design of an irreversible inhibitor is based on the
hypothesized LCAT catalytic mechanism. Analysing the docking
results, we could recognize two distinct pocket portions able to
bind: i) the cyclopentanoperhydrophenanthrene nucleus and ii) the
long-chain fatty acid, as schematically reported in Figure 2, panel
a. As previously mentioned, both these regions are strongly
hydrophobic. The demonstration that some of the identified
molecules are able to bind LCAT suggests that our distant
comparative modeling strategy allowed us to predict the shape of
the enzyme active site at a satisfactory approximation level.
A well-developed body of knowledge assigns to LCAT a central
role in intravascular HDL metabolism and in the determination of
plasma HDL levels. Knowledge of LCAT atomic structure is
expected to be very helpful in understanding its catalytic
mechanism and investigating its effect on atherogenesis. We
believe that our results show that the three-dimensional LCAT
model we generated represents a useful tool for the study of its
poorly characterized catalytic mechanism and, in perspective, for
the design of chemicals targeting LCAT active site.
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File S1 This file is organized in: Figure S1. Alignment
between: A) 2VTV2 and LCAT N-terminal part, B) 2VEO and
LCAT C-terminal part, used during the modeling procedures,
color-coded by similarity (BLOSUM62). Figure S2. LCAT 3D
model and its binding site. Protein structure is rendered with
ribbons and colored by modeling approach: residues from 1 to 43
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surface of the protein active site is colored according to CPK
colors (carbon in grey, oxygen in red and nitrogen in blue). Figure
S3. Interaction network of Glu149. Protein backbone is rendered
in ribbons, whereas residues’ side chains are rendered as sticks.
Figure S4. Interaction network of Lys 218. Protein backbone is
rendered in ribbons, whereas residues’ side chains are rendered as
sticks. Figure S5. Dose-response curves for the activity of a)
compound #1, b) compound #2 and c) heptadecylcholesteryl-R-
phosphonyl chloridate.
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